270 results about "Hepatovirus" patented technology

The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particular embodiments, the viral disease is viral hepatitis (e.g., hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E). Also featured are screening methods for identification of novel compounds that may be used to treat a viral disease.

The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particular embodiments, the viral disease is viral hepatitis (e.g., hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E) and the agent or combination of agents includes sertraline, a sertraline analog, UK-416244, or a UK-416244 analog. Also featured are screening methods for identification of novel compounds that may be used to treat a viral disease.

The invention involves A 1- beta-keto-5, 11(13)-diene eudesmane-12-acidum who has the structure as formula (1) shows and its medical salt, or solvate and its drug combinations and its medical usage in reducing hepatitis B surface antgien and inhibiting replication activity of aethyl- hepatovirus HBV-DNA medicinal. The invention compounds has strong inhibitory action in hepatitis B surface antgien (HBsAg) externalized by HepG2.2.15 cells and replication of aethyl- hepatovirus deoxyribonucleotide (HBV-DNA) in vitro, its inhibiting ability against HBsAg surpasses that of positive control Lamivudine in the same dose; it has obvious inhibiting ability against replication of aethyl- hepatovirus HBV-DNA under the concentration of 100 mu g/mL,20 mug/mL and 4 mug/mL DNA, it belongs to anti- aethyl- hepatovirus natural products of superactive non-nucleoside, can be expected for producing drugs for treating aethyl- hepatovirus infected disease.

The present invention relates to an eudesmane type sesquiterpene derivative 1 beta-hydroxyilicic acid, namely 1 beta-hydroxy-5 alpha H-eudesmane-11 (13)-ethylene-12-acid, its medicineal salt or solvent compound and its medicine composition and medicinal application for preparing medicine capable of curing hepatitis B virus infective disease and resisting hepatitis B virus. Said invention also provides its chemical structure formula.

The invention relates to the medicine technical field and concretely relates to a mixture formed by two enantiomorphous eremophilane acids separated from murrey ligularia and the officinal salt as well as the medicine combined material. The enantiomorphous eremophilane acid can be used for preparing the medicine curing hepatitis B virus infectious diseases due to the ability of suppressing the antigenic activity on the surface of hepatitis B virus.

The present invention provides for the treatment or prevention of Hepadnaviridae infection and disease caused by Hepadnaviridae infection. In particular, the invention provides compositions and methods that affect the ability of Hepadnaviridae to utilize the host's cellular machinery as part of the virus' lifecycle. The invention relates to the discovery that interfering with the normal ability of viruses to utilize the host cell machinery with LSD1 inhibitors reduces HBV replication. Thus, the treatment and prevention of Hepadnaviridae infection and disease caused by Hepadnaviridae according to the invention comprises administering to an individual in need of treatment, a therapeutically effective amount of a LSD1 inhibitor. The individual in need of treatment can be a human or, e.g., another mammal.

An immunoadjuvant used to prepare the antiviral vaccine or medicine for increasing the immune activity of the antigens for HBV, HCV, SARS coronavirus, fowl influenza virus, etc is a kind of human or animal's novel heat shock proteins gp96, hsp108 and hsp70.

The invention provides a phenanthridine compound with an effect of resisting hepatitis B and hepatitis C, a medicinal composition taking the same as an active medicine component, a preparation method and applications of the phenanthridine compound in preparing a medicine for resisting hepatitis C viruses, and preparing an anti-virus medicine. According to the invention, the activity of benzylphenethylamine alkaloid in resisting various viruses is discovered in a process of studying a plant anti-virus natural product, and an obvious effect in resisting viruses of hepatitis B and hepatitis C of a phenanthridine derivative is discovered through structure modification, structure-function relationship and structure optimization.

The invention discloses the medical application of a 15-methylene replaced andrographolide derivant as shown in general formula 1, more particularly relates to the application thereof in preparing anti-hepatitis B virus drugs, pertaining to the pharmaceutical chemistry field. HepG2.2.15 cells are used for detecting the secretory volumes of HBsAg and HBeAg and the HBV DNA level related to viral particles in the supernatant liquid of a nutrient solution, and the result shows that the 15-methylene replaced andrographolide derivant has good in-vitro anti-HBV effect. The 15-methylene replaced andrographolide derivant has better development and application prospect by being applied in preparing drugs used for treating and preventing Hepatitis B.

The invention belongs to the field of medical chemistry, relates to a fused tricyclic hepatitis virus inhibitor and application thereof, and particularly, provides a compound of the general formula I or pharmaceutically acceptable salt, isomer, solvate, crystal or prodrug thereof, and a medicine composition containing the compounds and application of the compounds or the composition in medicine preparation. The compound has the good inhibiting activity on hepatitis C virus, meanwhile has the low toxicity on host cells, and is high in effectiveness, good in safety and likely to become the medicine for treating and/or preventing diseases relevant to HCV infection.

The present invention provides a composition comprising hepatitis B virus (HBV) component(s), and which may be either nucleic acid- or polypeptide-based as well as nucleic acid molecules and vectors encoding such HBV component(s). It also relates to infectious viral particles and host cells comprising such nucleic acid molecules or vectors. It also provides composition and kits of parts comprising such nucleic acid molecules, vectors, infectious viral particles or host cells and the therapeutic use thereof for preventing or treating HBV infections.

The invention belongs to the field of hepatitis B virus infected cell models in life sciences and medicine, and provides a liver precursor-like cell model derived from a primary hepatocyte for hepatitis B virus infection, a preparation method and application. The liver precursor-like cell model consists of functional liver cells after three-dimensional differentiation, and the functional liver cells after three-dimensional differentiation are obtained by liver precursor-like cells obtained after in vitro conversion and cultivation of human primary hepatocytes after three-dimensional cultivation and liver maturation cultivation. Through experimental verification, after the liver precursor-like cell model is infected with HBV, the related genes of HBV infections such as RXRA, HNF4A, NTCP andthe like can be expressed highly, and the cell model can be used in hepatitis B virus infection research or can be co-cultured with HBV for preparing a hepatitis B virus infection cell model.

The invention discloses a multiple PCR (Polymerase Chain Reaction) detection kit for duck hepatitis A virus 1 and 3 as well as MDPV (Muscovy Duck Parvovirus). The detection kit contains three pairs of specific primers. Experimental results show the multiple PCR detection kit for duck hepatitis A virus 1 and 3 as well as MDPV can be applied to detecting the duck hepatitis A virus 1 and 3 and the MDPV. The multiple PCR detection kit has the advantages of being convenient to operate, high in sensitivity, strong in specificity and the like; furthermore, the multiple PCR detection kit can be clinically used for distinguishing and detecting the duck hepatitis A virus 1 and 3 and the MDPV, the time cost can be saved, and the pollution can be reduced.

The invention discloses a primer, a probe and a kit used for predicting liver cancer caused by hepatitis B virus (HBV). The primer and the probe are designed according to mutation sites of HBV. The mutation sites comprise the following 14: C1653T, T1674C, T1753V, A1762T, G1764A, A1846T, A1858T, G1896A, G1899A, C1485T, C1499H, G1613A, C3116T and T53C. According to the invention, early stage prediction of hepatocellular carcinoma is realized through detections upon the 14 mutation sites of HBV. Also, the invention provides a method for detecting HBV mutation sites.

The invention discloses a reagent kit for identifying duck hepatitis A virus infection and novel duck reovirus infection. Specific primers (such as SEQ No. (sequence number) 1-4) of a duck hepatitis A virus and a novel duck reovirus are adopted to establish a double PCR (Polymerase Chain Reaction) detection method, and assembled into the reagent kit. The reagent kit can identify the duck hepatitis A virus and the novel duck reovirus in the same system and the mixed infection of the duck hepatitis A virus and the novel duck reovirus. The reagent kit has the characteristics of quickness, accuracy, high sensitivity, good specificity and the like, and can well solve the problem that the duck hepatitis A virus infection and the novel duck reovirus infection are difficult to distinguish clinically.

The invention provides a kit for combined detection of hepatitis C virus antigen and antibody through chemiluminescence. According to the invention, the principles of chemiluminescence are utilized; anti-FITC-coated magnetic particles are bonded with an FITC-coated reagent and then undergo immunoreaction with a detected object; after immunoreaction of an AP-labeled substance, an immunoreaction chain (as shown in a figure 1 which is described in the specification) is constructed; luminous sensitivity of a substrate catalyzed by AP is far higher than enzyme immunoassay development, so reaction sensitivity is enhanced; meanwhile, FITC is used to simultaneously marking antigen and antibody, so hepatitis C virus antibody and core antigen are detected at the same time. The kit provided by the invention can more accurately detect hepatitis C, is free of leak detection, achieves the effect of early discovery and has a high application value in prevention of hepatitis C.

The invention discloses a construction method and use of a model of hepatitis B virus infection in vivo. The construction method of the model of hepatitis B virus infection in vivo, which uses stem cells of the human fetal liver in anti-hepatitis B virus medicament screening, comprises the following steps: separation and cultivation of the stem cells of the human fetal liver; immunohistochemical detection of the stem cells of the human fetal liver; hepatitis B virus serum infection of the stem cells of the human fetal liver; and verification of the infection of the stem cells of the human fetal liver by the hepatitis B viruses and the propagation of the viruses. The construction method, which uses the stem cells of the human fetal liver in the model of the infection in vivo, is used to screen and evaluate anti-hepatitis B virus medicaments. The method has the advantages that: the stem cells of the human fetal liver can be infected by the anti-hepatitis B viruses and constantly secrete anti-hepatitis B viruses; the stem cells of the human fetal liver can be passed and cultured; the method is simple and convenient; and the repeatability is desirable.

The invention provides a 7-acyl-15-oxo-spiraea lactone derivative which is a medicinal composition of medicinal active ingredients, a preparation method of the derivative, an application of the derivative in preparation of medicaments for resisting hepatitis C virus, and an application of the derivative in preparation of antivirus medicaments. In the process of studying plant antitumor natural products, 7-acyl-15-oxo-spiraea lactone is discovered to have activity of resisting various tumor cell strains, and most derivatives are stronger than a primer 15-oxo-spiraea lactone (1). The 7-acyl-15-oxo-spiraea lactone derivative is subjected to an activity test for inhibiting a Wnt signal channel, and the antitumor activity of the 7-acyl-15-oxo-spiraea lactone derivative is discovered to be in positive correlation with the activity of the 7-acyl-15-oxo-spiraea lactone derivative for inhibiting the Wnt signal channel.

The invention relates to a medicine combination and the application thereof in preparing preparations for treating chronic hepatitis B. The combination comprises a medicine combination with polysaccharide nucleic acid of bacillus calmette guerin as the active component and a Chinese traditional medicine combination, wherein the Chinese traditional medicine combination is prepared from astragalus, herba artemisiae scopariae, oldenlandia diffusa, herba lysimachiae, codonopsis pilosula, processed polygonum capitatum, salvia, radix paeoniae alba, chinaberry fruit, taraxacum, cortex moutan, poria and atractylodes; the polysaccharide nucleic acid of bacillus calmette Guerin is nonspecific immunity active reinforcer, and can effectively restrain the reproduction of hepatitis virus and promote the rapid negative turning of HBV-DNA and HbeAg; and the Chinese traditional medicine combination has the efficacy of invigorating qi and spleen, promoting blood circulation by removing blood stasis and clearing away heat and toxic material. The medicine combination can reduce the incidence rate of variation and drug resistance and effectively promote the improvement under the condition of improving the healing efficacy, and provides a novel, safe and effective drug choice for clinics.

The invention provides a hepatitis A virus monoclonal antibody, which is generated by secreting of a hybridoma cell strain with preservation number of CGMCC No.7859. The monoclonal antibody can specifically neutralize the antigen of hepatitis A virus with high efficiency, and has important meaning for diagnosis, prevention and treatment of the infection of hepatitis A virus.

A therapeutic DC vaccine for preventing and treating chronic hepatitis B is a hepatitis B specific DC vaccine carried by both HBsAg and HBcAg. The dendritic cells coming from mononuclear cells are carried by both recombinant HBV surface antigen and recombinant HBV core antigen.

The invention provides a fully humanized monoclonal antibody and a preparation method and application thereof, discloses the fully humanized monoclonal antibody which can specifically bind to a hepatitis B virus surface antigen, and can effectively inhibit hepatitis B virus infection of liver cells, and also discloses an encoding gene of the fully humanized monoclonal antibody and application of the fully humanized monoclonal antibody in preventing or treating the hepatitis B virus infection.